Browsing Tag
Bobak Azamian
1 post
Tarsus Pharmaceuticals (NASDAQ: TARS) to add Alkeus in $800m eye pipeline deal
Tarsus lines up an $800m Alkeus deal and a $125m PIPE to enter Stargardt disease, but a 2029 readout and Belite Bio's lead still gate the retina thesis.